返回 Agenda
Session 8 Track 3: Why Science Needs More Diversity in Clinical Trials
Session Chair(s)
Lori Mouser, PHARMD
Senior Director, Global Head of Oncology Scientific Engagement and Congresses
Daiichi Sankyo Inc., Switzerland
This session will focus on the scientific rationale for driving for more diversity in clinical trial programs. Ideas for how to ensure more diverse populations of patients have access to clinical trials as an option to treatment will be shared. Presenters will explore the role field teams can play in engaging with clinical trial sites.
Learning Objective : At the conclusion of this session, participants should be able to:- Identify examples of where race or gender differences lead to divergent clinical outcomes.
- Discuss reasons why broadening the diversity of patients across clinical trial programs is needed.
- Describe how field medical teams can support clinical trial sites in patient screening and enrollment.
Speaker(s)
Speaker
Danielle Day, PHD
Sobi, United States
Senior Medical Director, Immunology, Rare Disease
Speaker
Nicole Richie, PHD
Genentech, United States
Vice President & Global Head Health Equity & Population Science
Speaker
Bethsheba Johnson
Gilead Sciences, Inc, United States
Senior Director, HIV Prevention Field Director Western US